Samarendra Mohanty

Nanoscope Therapeutics Accelerates Sight-Restoring Drug Development with New Gene Therapy Manufacturing Partnership

by | Oct 18, 2022
Dallas-based Nanoscope Therapeutics is accelerating the development of therapies that could restore sight in patients with the help of a publicly traded firm. The retinal degenerative diseases-focused biotech company announced a new gene therapy manufacturing partnership with contract research organization Charles River Laboratories International.
MORE
EYE DNA DALLAS STARTUP GENE THERAPY
Bedford Biotech Restores “Meaningful Vision” in Blind Patients With Gene Therapy—and May Soon Go Public
by | Jun 22, 2021
Nanoscope Therapeutics successfully treated 11 patients blinded by advanced retinitis pigmentosa (RP). A single intravitreal injection produced positive results that persisted through one year. The startup plans a Phase 2b trial this summer and plans to develop gene therapies to treat more common retinal diseases—like dry age-related macular degeneration.
MORE